Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus Bio prices $200M convertible debt offering
11:29am, Wednesday, 15'th Apr 2020
Coherus BioSciences (NASDAQ:CHRS) has priced its $200M aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 in a private offering.Initial purchasers are granted an opti
Zacks: Brokerages Anticipate Coherus Biosciences Inc (NASDAQ:CHRS) Will Post Quarterly Sales of $119.21 Million
08:22am, Wednesday, 15'th Apr 2020
Analysts predict that Coherus Biosciences Inc (NASDAQ:CHRS) will report sales of $119.21 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Coherus Bioscienc
Coherus Biosciences (NASDAQ:CHRS) versus Editas Medicine (NASDAQ:EDIT) Head to Head Comparison
05:26am, Wednesday, 15'th Apr 2020
Coherus Biosciences (NASDAQ:CHRS) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
04:05am, Wednesday, 15'th Apr 2020
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subord
Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering
04:05am, Wednesday, 15'th Apr 2020
REDWOOD CITY, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the...
Coherus BioSciences Prices $—…….… Million Convertible Senior Subordinated Notes Offering
12:00am, Wednesday, 15'th Apr 2020Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering
11:52am, Tuesday, 14'th Apr 2020
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of
Wall Street Analysts Are Bullish on Top Healthcare Picks
11:18am, Tuesday, 14'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Coherus Biosciences (CHRS), Arcturus Therapeutics (ARCT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX), Coherus Biosciences (CHRS) and Delta 9 Cannabis (VRNDF).
Coherus BioSciences Announces Proposed Convertible Senior Subordinated Notes Offering
12:00am, Tuesday, 14'th Apr 2020Coherus Biosciences expects COVID-19 adverse effects to continue in Q2, 2H20 CHRS
01:44pm, Monday, 13'th Apr 2020
Coherus Biosciences expects COVID-19 adverse effects to continue in Q2, 2H20 CHRS
Coherus Biosciences sees Q1 revenue $115M-$117.5M, consensus $118.85M CHRS
01:44pm, Monday, 13'th Apr 2020
Coherus Biosciences sees Q1 revenue $115M-$117.5M, consensus $118.85M CHRS
